Kawasaki disease is a disease of young children that causes a high temperature (fever), a rash, and other typical symptoms (listed below). Most children recover fully but serious complications develop in some cases. Early treatment can prevent complications.
What is Kawasaki disease and who gets it?
It is an uncommon condition that mainly affects children aged under 5 years. It most commonly affects children aged 18-24 months. It causes various symptoms throughout the body (listed below). Kawasaki disease was first described in the 1960s by a Japanese doctor named Tomisaku Kawasaki. Since then cases have been reported in many countries.
Kawasaki disease is also occasionally known as mucocutaneous lymph node syndrome.
It is much more common in some countries than it is in others. It seems to be particularly common in Japan. It is less common in Europe and the USA. It affects boys more often than it affects girls. It seems to run in families. So it is more common in siblings or children of people who have had the disease in the past.
Kawasaki disease symptoms
A high temperature (fever) which lasts more than five days is usual. In addition, at least four of the following normally develop:
- Redness of the eyes (conjunctivitis).
- Changes in the mouth such as a red throat or tongue, or dry and cracked lips.
- A rash. This normally fades within a week.There is no specific 'Kawasaki rash' - the appearance may be different in different children. Most often there are raised red blotchy areas. It tends to affect a lot of the body, particularly the chest, tummy, back, groins, hands and feet.
- Changes in the hands or feet such as mild swelling or redness. The skin on some of the fingers or toes often peels after about 2-3 weeks.
- One or more lymph glands in the neck become swollen.
Also, affected children are commonly very irritable. The diagnosis is based on the above typical group of symptoms. There is no test to confirm the disease. Tests may be done to rule out other diseases that cause similar symptoms, such as measles, scarlet fever, etc.
Other symptoms may develop in addition to the above. These are less common and include:
- Being sick (vomiting).
- Tummy (abdominal) pains.
- Being off food.
- Joint swelling and pains.
- Skin going yellow (jaundice).
Typically, fever develops first and then the other symptoms (listed above) develop after a few days. Often, the symptoms that develop after the high temperature (fever) has started develop one after each other rather than all coming on at the same time. This is why the diagnosis may take several days to make after the initial fever starts. In total, symptoms tend to last up to 10 days before easing and going, although complications sometimes develop (see below).
During the illness, some children become very unwell, but others have a mild illness. This may be similar to many common infections that are caused by a virus. However, any child suspected of having Kawasaki disease is normally admitted to hospital, even if they appear to have a mild illness.
What causes Kawasaki disease?
The cause is not known. The symptoms seem rather like many common infections. However, it is not catching (contagious). It is rare for contacts of affected children also to become affected at the same time. This means that the cause is unlikely to be just an infection with a germ such as a bacterium or virus. It may be an unusual or severe reaction to a common virus that usually causes little or no harm to most people. However, no virus or other germ has been proved to cause this disease.
There seems to be some genetic tendency that increases the risk of developing the condition. For example, parents of children with Kawasaki disease are more likely to have had the condition themselves during childhood. Also, brothers and sisters have an increased risk of developing the condition. So, a theory is that affected children may have a genetic make-up that makes them 'overreact' to a common viral infection that does not cause problems in most children.
Kawasaki disease diagnosis
There is no specific test. So it is usually diagnosed on the basis of the typical features. Blood tests may point towards the diagnosis, or be used to rule out other possible diagnoses.
A heart scan (echocardiogram, or echo) is normally done to look for complications (see below). If complications do occur, they usually develop a week or so after the symptoms listed above. If heart complications occur, other types of scans may be used to monitor these over time.
Kawasaki disease treatment
- Aspirin. This is one of the few times aspirin is given to children. Aspirin helps to reduce the inflammation in the coronary arteries. It also helps to prevent clots in the blood. The flu jab (influenza vaccination) is usually given to children who have had aspirin treatment if they have not yet had their annual vaccination. This prevents some of the complications which can be caused by aspirin in children.
- Immunoglobulin. This is an antibody mixture obtained from human blood. It is given by a slow injection over a few hours (infusion) into the bloodstream. You may see it referred to as IVIg - intravenous immunoglobulin. It is not clear how it works. It may modify the response of the immune system in some way to prevent inflammation in the arteries.
Treatment with immunoglobulin given within 10 days of the onset reduces the chance of heart complications (see below). Without treatment, about 25 in 100 affected children develop an aneurysm. With treatment, this is reduced to fewer than 5 in 100. In some cases the immunoglobulin treatment is not effective and other options are tried.
Other treatments aim to make the child comfortable, such as giving lots to drink and nursing them through the acute feverish illness.
Research continues to search for better treatments. Some treatments which have been tried or are being studied are:
Further research is needed to confirm the role of these medicines in the treatment of Kawasaki disease.
If aneurysms have developed (see complications section below), a specialist heart doctor for children (a paediatric cardiologist) will be involved. In this situation, treatment is needed to prevent heart attacks or other heart problems developing. The child will have regular heart scans to keep an eye on what is happening. He or she may need another medicine to stop a blood clot. Very occasionally an operation is needed on the heart.
Some vaccines - particularly measles, mumps and rubella (MMR) - may need to be delayed for some months after IVIg treatment, which may cause them to be less effective.
Without treatment, up to 1 in 4 children who have Kawasaki disease develop inflammation of the blood vessels to the heart (coronary arteries). This can cause a swelling of a section of a coronary artery, which is called an aneurysm.
A coronary artery aneurysm usually causes no symptoms. Over time it often goes away and the artery returns to normal. However, the wall of an aneurysm is weakened and abnormal. Serious problems may develop in some children with an aneurysm. The most serious is that a clot (thrombosis) may develop in the aneurysm. The muscle of the heart is supplied with oxygen, carried in the blood of these arteries. If a clot develops, the muscle does not get enough oxygen. The heart muscle can then be damaged, causing a heart attack. Currently less than 1 in 100 children with Kawasaki disease die of heart problems.
An aneurysm can be detected by a heart scan (an echocardiogram, or echo). If an aneurysm does occur, it starts to develop a week or more after the fever and other acute symptoms begin. Treatment within 10 days of symptoms starting often prevents an aneurysm developing.
The aneurysm of a coronary artery is caused by inflammation of the artery (a 'vasculitis'). This swelling can occur in other arteries in various parts of the body, causing aneurysms elsewhere - but this is very rare. Various other rare problems have also been reported in some children with Kawasaki disease.
Kawasaki disease in adults
Kawasaki disease usually affects children. However in rare cases, it can occur in adults. Also, children who have had heart complications due to Kawasaki disease may continue to be affected by these when they reach adulthood. For example, women who had Kawasaki disease as children may not be able to have certain contraceptive pills, and may need specialist advice about whether it is safe for them to become pregnant.
Further reading and references
Fever in under 5s - assessment and initial management; NICE Guideline (updated August 2017)
McCrindle BW, Rowley AH, Newburger JW, et al; Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017 Apr 25135(17):e927-e999. doi: 10.1161/CIR.0000000000000484. Epub 2017 Mar 29.
Saguil A, Fargo M, Grogan S; Diagnosis and management of Kawasaki disease. Am Fam Physician. 2015 Mar 1591(6):365-71.
Pilania RK, Bhattarai D, Singh S; Controversies in diagnosis and management of Kawasaki disease. World J Clin Pediatr. 2018 Feb 87(1):27-35. doi: 10.5409/wjcp.v7.i1.27. eCollection 2018 Feb 8.
Wardle AJ, Connolly GM, Seager MJ, et al; Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017 Jan 271:CD011188. doi: 10.1002/14651858.CD011188.pub2.
Eleftheriou D, Levin M, Shingadia D, et al; Management of Kawasaki disease. Arch Dis Child. 2014 Jan99(1):74-83. doi: 10.1136/archdischild-2012-302841. Epub 2013 Oct 25.
Jamieson N, Singh-Grewal D; Kawasaki Disease: A Clinician's Update. Int J Pediatr. 20132013:645391. doi: 10.1155/2013/645391. Epub 2013 Oct 27.
Golshevsky D, Cheung M, Burgner D; Kawasaki disease--the importance of prompt recognition and early referral. Aust Fam Physician. 2013 Jul42(7):473-6.
Marchesi A, Tarissi de Jacobis I, Rigante D, et al; Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Ital J Pediatr. 2018 Aug 3044(1):102. doi: 10.1186/s13052-018-0536-3.
Marchesi A, Tarissi de Jacobis I, Rigante D, et al; Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. Ital J Pediatr. 2018 Aug 3044(1):103. doi: 10.1186/s13052-018-0529-2.